Improving Outcomes in Rheumatoid Arthritis
Treating to Target, IL-6-Directed Therapies, and Evolving Management Algorithms
Guidelines
2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis.
Singh JA, et al. Arthritis Rheumatol. 2016;68(1):1-26.
Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions
Smolen JS, et al. Ann Rheum Dis. 2013;72(4):482-492.
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update
Smolen JS, et al. Ann Rheum Dis. 2014;73(3):492-509.
Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force
Smolen JS, et al. Ann Rheum Dis. 2016;75(1):3-15.
Patient Resources
American College of Rheumatology Disease Overview
The American College of Rheumatology has published a concise overview to help patients and caregivers learn more about rheumatoid arthritis and provide tips for living well with this rheumatic disease.
American College of Rheumatology Patient Education Videos
The American College of Rheumatology has produced a library of videos about the impact of rheumatic disease, what to do when diagnosed with rheumatic disease, when to see a rheumatologist, and what patients have to say about their experiences of living with a rheumatic disease.
Handout on Health: Rheumatoid Arthritis
A publication from the National Institute of Arthritis and Musculoskeletal and Skin Diseases for people who have rheumatoid arthritis, as well as for their family members, friends, and others who want to find out more about this disease.
Suggested Readings
Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study
McInnes IB, et al. Ann Rheum Dis. 2015;74(4):694-702.
IL-6 inhibitors for treatment of rheumatoid arthritis: past, present, and future
Kim GW, et al. Arch Pharm Res. 2015;38(5):575-584.
IL-6 targeting compared to TNF targeting in rheumatoid arthritis: studies of olokizumab, sarilumab and sirukumab
Tanaka Y, Martin Mola E. Ann Rheum Dis. 2014;73(9):1595-1597.
Measures of rheumatoid arthritis disease activity
Anderson JK, et al. Arthritis Care Res (Hoboken). 2011;63(suppl 11):S14-S36.
The pathogenesis of rheumatoid arthritis
McInnes IB, Schett G. N Engl J Med. 2011;365(23):2205-2219.
Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: Results of a phase III study
Genovese MC, et al. Arthritis Rheumatol. 2015;67(6):1424-1437.
Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics
Dennis G Jr, et al. Arthritis Res Ther. 2014;16(2):R90.
Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial
Burmester GR, et al. Ann Rheum Dis. 2015.
Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year
Kremer JM, et al. Arthritis Rheum. 2011;63(3):609-621.
Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial
Gabay C, et al. Lancet. 2013;381(9877):1541-1550.
Interactive PresentationIL-6 in Rheumatoid Arthritis
From Pathophysiology to Individualized Therapy
Treating to Target, IL-6-Directed Therapies, and Evolving Management Algorithms
Relevant Resources
Improved Diagnostic and Management Strategies
Long-Term Management Strategies to Improve Patient Outcomes
Evidence-Based Strategies for Improved Patient Outcomes
Evolving Strategies for Diagnosis and Long-Term Management
Evolving Treatment Algorithms and Expert Perspectives on Biosimilars
Pathophysiology to the Management of Moderate-to-Severe Disease
Targeting Immune Dysregulation and Delivering Comprehensive Care
Translating Comprehensive Patient Evaluations Into Personalized Therapy
Looking Beyond Barriers to Optimize Therapy
New Perspectives on Targeting Remission and Individualizing Therapy
Using Imaging to Improve Patient Outcomes
Discussions and Debates on the Evolving Roles of Targeted Synthetic DMARDs
Translating Pathophysiology into Targeted Treatments
Think You Know JAK?
An Interactive Experience Highlighting Recent Clinical Advances
Debates & Discussions on the Evolving Role of JAK Inhibitors
The Evolving Role of JAK Inhibitors
Unpacking the Evidence for Their Use Today and Tomorrow
Unlocking Novel Paths to Patient Care
The Increasing Role of JAK Inhibitors
Unlocking Novel Paths to Patient Care
New Pathways to Patient Management
A Focus on Clinical Evidence and Guideline Recommendations
New Avenues to the Management of Severe Asthma
Getting on the Fast Track to Identify AxSpA
Interdisciplinary Strategies for Adult and Pediatric Patients
Interdisciplinary Management of Eosinophilic Esophagitis and Hereditary Angioedema
Finding the Path in Chronic Rhinosinusitis with Nasal Polyps
From Patient Evaluations to New Targeted Therapies
